Applied Molecular Transport Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMTI research report →
Companywww.appliedmt.com
Applied Molecular Transport Inc. , a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications.
- CEO
- Shawn M. Cross
- IPO
- 2020
- Employees
- 13
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $11.01M
- P/E
- -0.08
- P/S
- 0.00
- P/B
- 0.17
- EV/EBITDA
- 0.11
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -111.78%
- ROIC
- -129.95%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-125,431,000 · -30.10%
- EPS
- $-3.23 · -26.17%
- Op Income
- $-127,219,000
- FCF YoY
- -16.07%
Performance & Tape
- 52W High
- $0.84
- 52W Low
- $0.13
- 50D MA
- $0.19
- 200D MA
- $0.25
- Beta
- 2.29
- Avg Volume
- 320.19K
Get TickerSpark's AI analysis on AMTI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 27, 23 | EPIQ Capital Group, LLC | other | 2,149,292 |
| Dec 27, 23 | EPIQ Capital Group, LLC | other | 3,394,948 |
| Dec 27, 23 | EPIQ Capital Group, LLC | other | 2,500,000 |
| Dec 27, 23 | EPIQ Capital Group, LLC | other | 293,278 |
| Dec 27, 23 | VanDevender Aaron | sell | 20,000 |
| Dec 27, 23 | VanDevender Aaron | sell | 20,000 |
| Dec 27, 23 | VanDevender Aaron | sell | 212,659 |
| Dec 27, 23 | VanDevender Aaron | sell | 15,395 |
| May 24, 22 | Smither John W | sell | 20,000 |
| Dec 27, 23 | Smither John W | sell | 60,000 |
Our AMTI Coverage
We haven't published any research on AMTI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AMTI Report →